Rangel E.B.,University of Sao Paulo |
Rangel E.B.,Einstein Dialysis Center |
Andreoli M.C.,University of Sao Paulo |
Andreoli M.C.,Einstein Dialysis Center |
And 8 more authors.
Journal of Artificial Organs | Year: 2010
A severe disadvantage of administration of recombinant human erythropoietin to hemodialysis patients has been reported. A significant correlation has been shown with hemoglobin values determined online by use of the blood volume monitor (BVM) and by laboratory measurement. Online hemoglobin and hematocrit were measured by use of the BVM during hemodialysis session. Data were analyzed by t test and statistical significance was defined as a P of <0.05. Increases in the mean values of hemoglobin and hematocrit from 11.6 ± 1.9 to 13.9 ± 2.4 g/dL (17.4 ± 7.1%, P = 0.02) and from 34.4 ± 6.8 to 42 ± 8.3% (20.6 ± 8.8%, P = 0.022), respectively, were observed from the beginning to the end of dialysis. We hypothesize that a new strategy for adjusting erythropoietin dose may be based on hemoglobin and hematocrit values evaluated at the end of hemodialysis, when patients are no longer hypervolemic. Inadvertent high levels of hemoglobin could be one explanation why patients present higher rates of cardiovascular and access-related events, especially when monitored online by use of the BVM to achieve the dry weight. © 2010 The Japanese Society for Artificial Organs. Source